TuHURA Biosciences Announces $650K Draw on $50M Revolving Credit Facility

What Happened
TuHURA Biosciences, Inc. filed an 8-K to report a new draw under its previously disclosed Loan Agreement with Parkview Holdings One LLC. The Loan Agreement (entered April 21, 2026) provides a revolving credit facility with up to $50.0 million in availability and a maturity date of April 21, 2031. On September 21, 2026, TuHURA received and borrowed an additional $650,000 and said it expects to use the funds for general corporate purposes.

Key Details

• Loan Agreement counterparty: Parkview Holdings One LLC; agreement date April 21, 2026.
• Facility size and term: up to $50.0 million in revolving availability; maturity April 21, 2031.
• Recent activity: $650,000 additional draw on September 21, 2026.
• Documentation: full Loan Agreement was filed as Exhibit 4.1 to the Company’s Form 8-K on April 22, 2026; this 8-K references that agreement.

Why It Matters
This filing confirms TuHURA is using its credit facility to access cash for operations and corporate needs, which affects the company’s near-term liquidity. Investors should note the existence of a committed multi-year credit line (up to $50M) and the recent $650K draw as a concrete use of that facility. The company’s 8-K also highlights typical forward-looking risk language, including the possibility that conditions to draw or maintain the loan may not be met and a disclosed potential conflict of interest because the lender is affiliated with the company’s largest stockholder.